A global leader in data-driven medicine, Sophia Genetics, has announced that hospitals in Morocco, Cameroon and South Africa have started integrating the company’s AI for clinical genomics, SOPHiA, into their clinical workflow to advance patients’ care.
Medical institutions using SOPHiA in Africa include The Centre for Proteomic & Genomic Research (CPGR) in Cape Town; The Bonassama District Hospital in Cameroon; and PharmaProcess, ImmCell, The Al Azhar Oncology Center, The Riad Biology Center and The Oudayas, Medical Analysis Laboratory in Morocco.
The aforementioned hospitals are adopting SOPHiA to analyse genomic data to identify disease-causing mutations in patients’ genomic profiles, and decide on the most effective care.
As new users of SOPHiA, the hospitals join a larger network of 260 hospitals in 46 countries that share clinical insights across patient cases and patient populations, which feeds a knowledgebase of biomedical findings to accelerate diagnostics and care.
“Since inception, our vision has been to develop innovative technological solutions that analyse patients’ genomic profiles to offer better diagnosis and care to the greatest number of patients, wherever they live. I am very proud that SOPHiA is triggering a technological leapfrog movement in healthcare across Africa,” said Sophia Genetics’ CEO and Co-founder, Dr Jurgi Camblong.
“By joining our community, African hospitals are breaking down the technological barriers that prevented African patients from benefiting from the same level of genomic testing than patients from the best medical centres worldwide. This is a story about accessibility, democratisation, empowerment, and hope,” continued Dr Camblong.
Among other diseases, SOPHiA will be a key partner for African hospitals in oncology. Lack of relevant diagnostics and personalised care means that 60% of women with breast cancer in Africa die compared to 20% in the US and EU. According to a 2012 global report from the International Prevention Research Institute (iPRI), an earlier diagnostic of breast cancer could increase life expectancy by 30%.
As oncology expertise might be based in different places across the globe, SOPHiA ensures that the knowledge of a specialist in Paris, for example, will be accessible to save patients in Nairobi.
“In creating a first-of-its-kind genomic medicine offering in Africa, using SOPHiA has been beneficial because its analysis are used by a global community of genomic medicine practitioners, allowing us to offer a best-in-class service,” said Managing Director at the CPGR, Dr Reinhard Hiller.
“After Europe, Canada, Australia, Russia, and Latin America, the adoption of SOPHiA in Africa is perhaps the strongest evidence that the democratisation of data-driven medicine is changing scale to help the highest number of patients, wherever they live across the globe,” concluded Dr Camblong.